drugset / Trial / NCT00704600

Nelfinavir, a Phase I/Phase II Rectal Cancer Study

NCT00704600

Phase 1/2 Completed 15 enrolled Maastricht Radiation Oncology
NaSingle-groupOpen-labelTreatment

Summary

The aim is to study safety and activity of nelfinavir , added to standard chemoradiotherapy in patients with locally advanced rectal cancer. Furthermore analysis of the effect of nelfinavir combined with chemoradiation on tumour tissue will be studied

Timeline

Start
2008-09
Primary completion
2010-09
Completion
2013-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Nelfinavir Other / unclassified 750 mg Oral
Subject Nelfinavir Other / unclassified 1250 mg Oral

Indications